BRIEF REPORT
Cystic fibrosis drug approved for patients aged 6-11 years worked well in clinical practice
Ioanna Loukou,
Corresponding Author
Ioanna Loukou
Cystic Fibrosis Department, Agia Sofia Children’s Hospital, Athens, Greece
Correspondence
Ioanna Loukou, Cystic Fibrosis Department, Agia Sofia Children’s Hospital, Thivon and Papadiamantopoulou, Athens 11527, Greece.
Email: [email protected]
Search for more papers by this author Argyri Petrocheilou,
Argyri Petrocheilou
Cystic Fibrosis Department, Agia Sofia Children’s Hospital, Athens, Greece
Search for more papers by this author Maria Moustaki,
Maria Moustaki
Cystic Fibrosis Department, Agia Sofia Children’s Hospital, Athens, Greece
Search for more papers by this author Christina N. Katsagoni,
Christina N. Katsagoni
Cystic Fibrosis Department, Agia Sofia Children’s Hospital, Athens, Greece
Search for more papers by this author Konstantinos Douros,
Konstantinos Douros
Pediatric Allergy and Respiratory Unit, 3rd Department of Pediatrics, School of Medicine, “Attikon” University Hospital, National and Kapodistrian University of Athens, Athens, Greece
Search for more papers by this author
Ioanna Loukou,
Corresponding Author
Ioanna Loukou
Cystic Fibrosis Department, Agia Sofia Children’s Hospital, Athens, Greece
Correspondence
Ioanna Loukou, Cystic Fibrosis Department, Agia Sofia Children’s Hospital, Thivon and Papadiamantopoulou, Athens 11527, Greece.
Email: [email protected]
Search for more papers by this author Argyri Petrocheilou,
Argyri Petrocheilou
Cystic Fibrosis Department, Agia Sofia Children’s Hospital, Athens, Greece
Search for more papers by this author Maria Moustaki,
Maria Moustaki
Cystic Fibrosis Department, Agia Sofia Children’s Hospital, Athens, Greece
Search for more papers by this author Christina N. Katsagoni,
Christina N. Katsagoni
Cystic Fibrosis Department, Agia Sofia Children’s Hospital, Athens, Greece
Search for more papers by this author Konstantinos Douros,
Konstantinos Douros
Pediatric Allergy and Respiratory Unit, 3rd Department of Pediatrics, School of Medicine, “Attikon” University Hospital, National and Kapodistrian University of Athens, Athens, Greece
Search for more papers by this author
First published: 06 August 2020
No abstract is available for this article.
CONFLICT OF INTEREST
Ioanna Loukou has received advisory board reimbursements from Vertex Pharmaceuticals. The other authors have no conflicts of interest to declare.
| Filename |
Description |
| apa15519-sup-0001-FigS1.docxWord document, 93 KB |
Fig S1 |
| apa15519-sup-0002-TableS1.docxWord document, 13.2 KB |
Table S1 |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Debray D, Narkewicz MR, Bodewes F, et al. Cystic fibrosis-related liver disease: research challenges and future perspectives. J Pediatr Gastroenterol Nutr. 2017; 65: 443-448.
- 2Ratjen F, Hug C, Marigowda G, et al. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. Lancet Respir Med. 2017; 5: 557-567.
- 3Wu HX, Zhu M, Xiong XF, Wei J, Zhuo KQ, Cheng DY. Efficacy and safety of CFTR corrector and potentiator combination therapy in patients with cystic fibrosis for the F508del-CFTR homozygous mutation: a systematic review and meta-analysis. Adv Ther. 2019; 36: 451-461.
- 4Habib AR, Kajbafzadeh M, Desai S, Yang CL, Skolnik K, Quon BS. A systematic review of the clinical efficacy and safety of CFTR modulators in cystic fibrosis. Sci Rep. 2019; 9: 7234.
